Two-layered dissolving microneedles formulated with intermediate-acting insulin

被引:73
|
作者
Ito, Yukako [1 ]
Hirono, Muneyuki [1 ]
Fukushima, Keizo [2 ]
Sugioka, Nobuyuki [2 ]
Takada, Kanji [1 ]
机构
[1] Kyoto Pharmaceut Univ, Dept Pharmacokinet, Yamashina Ku, Kyoto 6078412, Japan
[2] Kobe Gakuin Univ, Fac Pharmaceut Sci, Dept Clin Pharmacokinet, Kobe, Hyogo, Japan
关键词
Insulin analog; Dissolving microneedles; Protamine sulfate insulin; Two-layered; Transdermal delivery; Relative pharmacological availability; Rats; CHONDROITIN SULFATE PROTEOGLYCAN; PERCUTANEOUS-ABSORPTION; DRUG-DELIVERY; MICROPILES; CHITOSAN; ROUTES; NASAL;
D O I
10.1016/j.ijpharm.2012.06.047
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Two-layered dissolving microneedles (DMs) containing intermediate-acting insulin, protamine sulfate insulin (PSI), were prepared. Then a pharmacodynamic study was performed to evaluate the prolonged hypoglycemic effects in rats. The DMs were approximately 497 +/- 5 mu m long, with 303 +/- 3 mu m diameter at their base. The length of the insulin loaded space was 182 +/- 4 mu m. PSI contents in DMs were 0.51 +/- 0.02 IU. A three-month stability study showed that 99.9 +/- 1.4% of PSI was recovered at 4 degrees C. As the temperature increased to 40 degrees C, recovery decreased to 97.5 +/- 2.0%. PSI was released within 5 min from DMs. Hypoglycemic effects of PSI DMs were evaluated in rats where subcutaneous injection preparations were used as references. Total area above the plasma glucose level (% of the pre-dose level) vs. time curve as an index of hypoglycemic effect was 144.0 +/- 16.0% h and 243.3 +/- 8.5% h for PSI DMs at 1.46 and 3.28 IU/kg. The relative pharmacologic availability of PSI from DMs were 100.2 +/- 9.8% and 91.4 +/- 4.1%. No significant difference of hypoglycemic curves was found between DMs and injection solutions, which suggests the usefulness of two-layered DMs of PSI for the displacement therapy of sc injection preparation. (c) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:387 / 393
页数:7
相关论文
共 50 条
  • [31] Time-action profiles of the intermediate-acting insulin analogue - Des(64,65)-human proinsulin
    Heinemann, L
    Heise, T
    Klepper, A
    Ampudia, J
    Bender, R
    Starke, AAR
    DIABETES & METABOLISM, 1995, 21 (06): : 415 - 419
  • [32] Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products
    Bullano, MF
    Al-Zakwani, IS
    Fisher, MD
    Menditto, L
    Willey, VJ
    CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (02) : 291 - 298
  • [33] SYNTHESIS AND BIOACTIVITY OF DES(64,65)-HUMAN PROINSULIN (D), A SOLUBLE, INTERMEDIATE-ACTING INSULIN AGONIST
    HOFFMANN, JA
    CHANCE, RE
    CUSICK, T
    RABE, CA
    TINSLEY, FC
    WILLIAMS, VK
    MYERS, SR
    DIABETES, 1993, 42 : A54 - A54
  • [34] Insulin Glargine Versus Intermediate-Acting Insulin as the Basal Component of Multiple Daily Injection Regimens for Adolescents with Type 1 Diabetes Mellitus
    Chase, H. Peter
    Arslanian, Silva
    White, Neil H.
    Tamborlane, William V.
    JOURNAL OF PEDIATRICS, 2008, 153 (04): : 547 - 553
  • [35] Long-acting insulin analogs versus intermediate-acting insulin and the risk of major adverse cardiovascular events among patients with type 2 diabetes in the United Kingdom
    Brunetti, Vanessa C.
    Yu, Oriana
    Platt, RobertW
    Filion, Kristian B.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 104 - 104
  • [36] Restorative biodegradable two-layered hybrid microneedles for melanoma photothermal/chemo co-therapy and wound healing
    Yue Shan
    Bowen Tan
    Min Zhang
    Xi Xie
    Jinfeng Liao
    Journal of Nanobiotechnology, 20
  • [37] Descriptive Analysis of Long- and Intermediate-Acting Insulin and Key Safety Outcomes in Adults with Type 2 Diabetes Mellitus
    Kent, Daniel J.
    McMahill-Walraven, Cheryl N.
    Panozzo, Catherine A.
    Pawloski, Pamala A.
    Haynes, Kevin
    Marshall, James
    Brown, Jeffrey
    Eichelberger, Bernadette
    Lockhart, Catherine M.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2019, 25 (11): : 1162 - 1171
  • [38] Restorative biodegradable two-layered hybrid microneedles for melanoma photothermal/chemo co-therapy and wound healing
    Shan, Yue
    Tan, Bowen
    Zhang, Min
    Xie, Xi
    Liao, Jinfeng
    JOURNAL OF NANOBIOTECHNOLOGY, 2022, 20 (01)
  • [39] Glycaemic control and hypoglycaemia in children, adolescents and young adults with unstable type 1 diabetes mellitus treated with insulin glargine or intermediate-acting insulin
    Herwig, Juergen
    Scholl-Schilling, Gabriele
    Boehles, Hans
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2007, 20 (04): : 517 - 525
  • [40] Nighttime insulin kinetics and glycemic control in type 1 diabetes patients following administration of an intermediate-acting lispro preparation
    Janssen, MMJ
    Casteleijn, S
    Deville, W
    PoppSnijders, C
    Roach, P
    Heine, RJ
    DIABETES CARE, 1997, 20 (12) : 1870 - 1873